XBiotech Inc (NASDAQ:XBIT) Director W Thorpe Mckenzie acquired 2,900 shares of the business’s stock in a transaction that occurred on Monday, November 12th. The stock was acquired at an average price of $3.74 per share, for a total transaction of $10,846.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
W Thorpe Mckenzie also recently made the following trade(s):
- On Thursday, October 4th, W Thorpe Mckenzie sold 385,000 shares of XBiotech stock. The shares were sold at an average price of $3.00, for a total transaction of $1,155,000.00.
- On Friday, September 7th, W Thorpe Mckenzie sold 6,234 shares of XBiotech stock. The shares were sold at an average price of $3.65, for a total transaction of $22,754.10.
NASDAQ XBIT traded down $0.03 during trading hours on Tuesday, hitting $3.99. The company’s stock had a trading volume of 14,136 shares, compared to its average volume of 48,763. XBiotech Inc has a twelve month low of $2.13 and a twelve month high of $5.80.
A number of hedge funds and other institutional investors have recently made changes to their positions in XBIT. LMR Partners LLP acquired a new position in XBiotech in the second quarter valued at approximately $154,000. Dimensional Fund Advisors LP lifted its holdings in XBiotech by 47.4% in the first quarter. Dimensional Fund Advisors LP now owns 37,610 shares of the biopharmaceutical company’s stock valued at $201,000 after buying an additional 12,099 shares during the period. Paloma Partners Management Co lifted its holdings in XBiotech by 479.1% in the second quarter. Paloma Partners Management Co now owns 89,025 shares of the biopharmaceutical company’s stock valued at $399,000 after buying an additional 73,652 shares during the period. Finally, Millennium Management LLC acquired a new position in XBiotech in the second quarter valued at approximately $931,000. Institutional investors and hedge funds own 5.01% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “XBiotech Inc (XBIT) Director W Thorpe Mckenzie Buys 2,900 Shares” was posted by WKRB News and is the sole property of of WKRB News. If you are accessing this story on another website, it was stolen and republished in violation of United States & international copyright & trademark legislation. The correct version of this story can be accessed at https://www.wkrb13.com/2018/11/14/xbiotech-inc-xbit-director-w-thorpe-mckenzie-buys-2900-shares.html.
XBiotech Inc, a pre-market biopharmaceutical company, engages in discovering and developing True Human monoclonal antibodies for treating various diseases. The company's lead product is Xilonix, which is also known as MABp1, a therapeutic antibody that neutralizes interleukin-1 alpha, which has completed Phase III clinical trial in Europe for the treatment of symptomatic and advanced colorectal cancer.
Recommended Story: Balance Sheet
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.